For Numab News Today

Press release content from Business Wire. The AP news staff was not involved in its creation.

WAEDENSWIL, Switzerland--(BUSINESS WIRE)--May 20, 2021-- Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, ...